Skip to main content
. 2014 Feb;33(2):105–114. doi: 10.5732/cjc.012.10274

Figure 1. Flow chart showing the process of trial selection in patients with non–small cell lung cancer (NSCLC).

Figure 1.

OS, overall survival; PBC, platinum-based doublet chemotherapy; TKIs, tyrosine kinase inhibitors.